UPDATE: Jefferies Starts Dyne Therapeutics (DYN) at Buy

October 12, 2020 12:41 AM EDT
Get Alerts DYN Hot Sheet
Price: $17.94 -0.72%

Rating Summary:
    5 Buy, 0 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 18 | Down: 14 | New: 23
Trade Now! 
Join SI Premium – FREE
(Updated - October 12, 2020 8:39 AM EDT)

(updated to add analyst comments)

Jefferies analyst Eun Yang initiates coverage on Dyne Therapeutics (NASDAQ: DYN) with a Buy rating and a price target of $47.00.

The analyst commented, "DYN's FORCE platform enables muscle tissue-specific delivery of oligonucleotidetherapy for serious muscle diseases, overcoming current limitation. Though still earlystages, encouraging preclinical data set DYN apart from competitors. For lead programDM1 (>$10B US market size; no approved drug), if human PoC data is positive in ~2022,we see significant upside. For 2021, we expect additional preclinical data bolstering itsapproach to drive upside from here."

For an analyst ratings summary and ratings history on Dyne Therapeutics click here. For more ratings news on Dyne Therapeutics click here.

Shares of Dyne Therapeutics closed at $18.64 yesterday.

You May Also Be Interested In

Related Categories

Analyst Comments, Hot New Coverage, New Coverage

Related Entities

Jefferies & Co